Skip to main content

Table 3 NNH for frequently occurring TEAEs (>5 %) in patients treated with droxidopa during randomized treatment

From: Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension

TEAE NOH301/302 NOH306 Pooled
Droxidopa (n = 131) Placebo (n = 132) Droxidopa (n = 114) Placebo (n = 108) Droxidopa (n = 245) Placebo (n = 240)
Headache, n (%) 8 (6.1) 4 (3.0) 15 (13.2) 8 (7.4) 23 (9.4) 12 (5.0)
 NNH (95 % CI) 33 (NS)   18 (NS)   23 (NS)  
Dizziness, n (%) 5 (3.8) 2 (1.5) 11 (9.6) 5 (4.6) 16 (6.5) 7 (2.9)
 NNH (95 % CI) 44 (NS)   20 (NS)   28 (NS)  
Nausea, n (%) 2 (1.5) 2 (1.5) 10 (8.8) 5 (4.6) 12 (4.9) 7 (2.9)
 NNH (95 % CI) 8647 (NS)   20 (NS)   51 (NS)  
Fatigue, n (%) 2 (1.5) 3 (2.3) 8 (7.0) 6 (5.6) 10 (4.1) 9 (3.8)
 NNH (95 % CI) –135 (NS)   69 (NS)   302 (NS)  
Hypertension, n (%) 2 (1.5) 0 8 (7.0) 1 (0.9) 10 (4.1) 1 (0.4)
 NNH (95 % CI) 66 (NS)   17 (NS)   28 (15.9–94.6)  
  1. NNH number needed to harm, NS not significant due to boundaries that include 0, TEAE treatment-emergent adverse event